Aace Comprehensive Diabetes Management Algorithm 2013

Garber, Alan J.; Abrahamson, Martin J.; Barzilay, Joshua I.; Blonde, Lawrence; Bloomgarden, Zachary T.; Bush, Michael D.; Dagogo‐Jack, Samuel; Davidson, Michael; Einhorn, Daniel; Garvey, W. Timothy; Grunberger, George; Handelsman, Yehuda; Hirsch, Irl B.; Jellinger, Paul S.; McGill, Janet B.; Mechanick, Jeffrey I.; Rosenblit, Paul D.; Umpiérrez, Guillermo E.; Davidson, Michael

doi:10.4158/endp.19.2.a38267720403k242

Cited by 336 publications

(377 citation statements)

References 0 publications

Supporting

Mentioning

362

Contrasting

Unclassified

Order By: Relevance

“…GLP-1 receptor agonists are one of the classes that should be considered as add-on therapy in those patients in whom metformin alone or in combination with another oral agent is inadequate for hyperglycaemic control [2,23,24]. In addition to their ability to reduce HbA 1c , the GLP-1 receptor agonists are associated with modest loss of body weight [25], which may be considered an advantage compared with the weight gain that is often seen with insulin therapy.…”

Section: Discussionmentioning

confidence: 99%

“…Although metformin remains the preferred initial drug of choice for treatment of newly diagnosed type 2 diabetes, current treatment guidelines do not specify which class of glucose-lowering medication should be added in patients who are inadequately controlled with metformin alone [2,23,24]. GLP-1 receptor agonists are one of the classes that should be considered as add-on therapy in those patients in whom metformin alone or in combination with another oral agent is inadequate for hyperglycaemic control [2,23,24].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea

Weissman¹,

Carr

et al. 2014

Diabetologia

111

View full text Add to dashboard Cite

Aims/hypothesis The aim of this study was to compare the efficacy and safety of once-weekly albiglutide with once-daily insulin glargine (A21Gly,B31Arg,B32Arg human insulin) in patients with type 2 diabetes inadequately controlled on metformin with or without sulfonylurea. Methods This was a randomised, open-label, multicentre (n=222), parallel-group, non-inferiority out-patient clinical trial, with 779 patients enrolled in the study. The study was conducted in 222 centres located in four countries. Patients aged ≥18 years with type 2 diabetes treated with metformin (±sulfonylurea) for at least 3 months with a baseline HbA 1c 7.0-10.0% (53.0-85.8 mmol/mol) were randomly assigned (2:1) via a computer-generated randomisation sequence with a voice response system to receive albiglutide (30 mg once a week, n=504) or insulin glargine (10 U once a day, n=241) added to current therapy. Participants and investigators were not masked to treatment assignment. Doses of each medication were adjusted on the basis of the glycaemic response. The primary endpoint was change from baseline in HbA 1c at week 52. Results In the albiglutide group, HbA 1c declined from 8.28± 0.90% (67.0±9.8 mmol/mol) (mean±SD) at baseline to 7.62± 1.12% (59.8±12.2 mmol/mol) at week 52. A similar reduction occurred in the insulin glargine group (8.36±0.95% to 7.55± 1.04% [67.9±10.4 to 59.0±11.4 mmol/mol]). The modeladjusted treatment difference of 0.11% (95% CI −0.04%, 0.27%) (1.2 mmol/mol [95% CI −0.4, 3.0 mmol/mol]) indicated non-inferiority of albiglutide to insulin glargine based on the pre-specified non-inferiority margin of 0.3% (3.3 mmol/mol, p=0.0086). Body weight increased in the insulin glargine group and decreased in the albiglutide group, with a mean treatment difference of −2.61 kg (95% CI −3.20, −2.02; p<0.0001). Documented symptomatic hypoglycaemia occurred in a higher proportion of patients in the insulin glargine group than in the albiglutide group (27.4% vs 17.5%, p=0.0377). Conclusions/interpretation Albiglutide was non-inferior to insulin glargine at reducing HbA 1c at week 52, with modest weight loss and less hypoglycaemia. Both drugs were well tolerated. Albiglutide may be considered an alternative to insulin glargine in this patient population. Trial registration: ClinicalTrials.gov NCT00838916 (completed) Funding: This study was planned and conducted by GlaxoSmithKline.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea

Weissman¹,

Carr

et al. 2014

Diabetologia

111

View full text Add to dashboard Cite

show abstract

“…Sulfonylureas, such as glyburide, glipizide, and glimepiride, are commonly used as second-line therapies in T2DM 26,27 . However, hard endpoints with sulfonylureas have not been well evaluated in ethnic populations.…”

Section: Sulfonylureasmentioning

confidence: 99%

“…Clinical algorithms for the treatment of T2DM outline a multi-faceted approach that combines lifestyle optimization and pharmacotherapy 26,27 . The AACE (American Association of Clinical Endocrinologists) algorithm encourages individualized therapies that depend on HbA 1c targets and other patient characteristics.…”

Section: Biguanides: Metforminmentioning

confidence: 99%

Racial/ethnic disparities in prevalence and care of patients with type 2 diabetes mellitus

Ferdinand

Nasser

2015

Current Medical Research and Opinion

View full text Add to dashboard Cite

Background: As of 2012, nearly 10% of Americans had diabetes mellitus. People with diabetes are at approximately double the risk of premature death compared with those in the same age groups without the condition. While the prevalence of diabetes has risen across all racial/ethnic groups over the past 30 years, rates are higher in minority populations. The objective of this review article is to evaluate the prevalence of diabetes and disease-related comorbidities as well as the primary endpoints of clinical studies assessing glucoselowering treatments in African Americans, Hispanics, and Asians.

show abstract

“…In addition, the AACE has an algorithm specific for prediabetes management [18] . These recommendations and algorithm were developed for all healthcare providers, and can be used in any healthcare setting, with the goal of maintaining normal blood pressure, lipid and glucose control.…”

Section: Implications For Practicementioning

confidence: 99%

Prevalence of normoglycemic, prediabetic and diabetic A1c levels

Aponte¹

2013

WJD

View full text Add to dashboard Cite

AIM:To investigate normoglycemic, prediabetic and diabetic A1c levels in those with prediabetes; and prediabetic and diabetic A1c levels in those with non-prediabetes. METHODS:The National Health and Nutritional Examination Survey (NHANES) 2007-2008 and NHANES 2009-2010 were utilized to examine and compare trends and differences among five different ethnic groups (Mexican Americans, Other Hispanics, NonHispanic Whites, Non-Hispanic Blacks, Other/Multiracials) with normoglycemic, prediabetic and diabetic A1c levels with self-reported prediabetes and prediabetic and diabetic A1c levels in those with self-reported non-prediabetes. Sample participants of the five ethnic groups were limited to those 20 years of age and older, who had completed the diabetes questionnaire and had A1c measured. Descriptive statistics were computed for all variables. χ 2 were performed on all five ethnic groups to examine significant differences of normoglycemic, prediabetic and diabetic A1c levels in those with self-reported prediabetes, and prediabetic and diabetic A1c levels in those with self-reported non-prediabetes. Blacks who self-reported prediabetes, there were significant differences (P = 0.0001) for all A1c levels (normoglycemic, prediabetic and diabetic A1c levels). For Other/Multi-racials with self-reported prediabetes there was significant differences in those with normoglycemic (P = 0.0104) and diabetic (P = 0. RESULTS: CONCLUSION:The findings highlight the need of prediabetes awareness and of education in the community

show abstract

Aace Comprehensive Diabetes Management Algorithm 2013

Cited by 336 publications

References 0 publications

HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea

HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea

Racial/ethnic disparities in prevalence and care of patients with type 2 diabetes mellitus

Prevalence of normoglycemic, prediabetic and diabetic A1c levels

Contact Info

Product

Resources

About